证券代码：688739 证券简称：成大生物 公告编号：2025-055 辽宁成大生物股份有限公司 关于召开 2025 年第三季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 21 日（星期五）至 11 月 27 日（星期四）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 lncdsw@cdbio.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 辽宁成大生物股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日发布 公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第 三季度的经营成果、财务状况，公司计划于 2025 年 11 月 28 日上午 9:00-10:00 举行 2025 年第三季度业绩说 ...

上市首日即跌破发行价，四年漫漫熊途，这只生物制品股的"割肉"教材 2021年10月，当一家生物制品公司以110元的天价新股身份登陆A股市场时，众多幸运中签的投资者满怀憧憬，期待着一笔数万元的丰厚收益。然而，现实 却以一种残酷的方式，瞬间击碎了他们的美梦。上市当天，股价便遭遇"开门黑"，盘中最高价仅触及83.69元，未能触及发行价的"边"，收盘价定格在76.40 元，让每一位中签者直接蒸发16800元。 但这仅仅是漫长下跌的序幕，而非噩梦的终结。这家公司，创造了A股市场一个令人瞠目结舌的记录，开启了长达四年的价值毁灭之旅。 股价犹如断了线的风筝，一路向下，毫无悬念。时至2022年12月，其股价已然跌至29元，相比发行价蒸发了66%，一签的账面亏损更是扩大至惊人的40500 元。尽管市场一度以为跌势将止，经历了一年的横盘震荡，投资者们试图从中寻找一丝曙光，但2024年1月，悲剧再次重演。股价又一次选择了下跌通道， 直至22元才勉强企稳。从发行价算起，跌幅已然超过80%。这意味着，任何在上市初期中签后选择持有，抑或是试图通过补仓摊薄成本的投资者，其初始本 金几乎已所剩无几。 成大生物 ▽ 688739 科创 融 沪 ...

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]

Core Viewpoint - Chengda Biological announced that it will not implement a share buyback by October 2025 [1] Summary by Relevant Categories - Company Announcement - Chengda Biological released a notice on November 3, stating that it will not carry out a share repurchase by October 2025 [1]

证券代码：688739 证券简称：成大生物 公告编号：2025-054 辽宁成大生物股份有限公司 公司于2025年6月19日召开第五届董事会第十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》。公司拟使用不低于人民币1,000万 元（含）且不超过人民币2,000万元（含）的超募资金以集中竞价交易方式回购公 司人民币普通股股票，用于实施员工持股计划或股权激励，回购股份的价格为不 超过人民币38.00元/股（含），回购股份期限为自公司董事会审议通过本次回购股 份方案之日起不超过12个月。具体内容详见公司于2025年6月20日在上海证券交易 所网站（www.sse.com.cn）披露的《辽宁成大生物股份有限公司关于以集中竞价交 易方式回购公司股份的回购报告书》（公告编号：2025-034）。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | --- | --- | --- | ...

Core Viewpoint - The company plans to repurchase shares using excess funds raised, with a focus on employee stock ownership plans or equity incentives, indicating a commitment to enhancing shareholder value and employee engagement [1] Summary by Sections Share Repurchase Plan - The company intends to use between 10 million to 20 million yuan of excess funds for share repurchase through centralized bidding [1] - The maximum repurchase price is set at 38 yuan per share, with the repurchase period extending until June 18, 2026 [1] Current Repurchase Status - As of October 31, 2025, the company has repurchased a total of 384,899 shares, which represents 0.092% of the total share capital [1] - The total amount paid for the repurchased shares is 10.7892 million yuan, with individual repurchase prices ranging from 27.20 yuan to 29.61 yuan per share [1] - No repurchase activity was conducted in October [1]

Core Viewpoint - The company plans to use up to RMB 700 million of idle raised funds for cash management, ensuring that it does not affect the implementation of investment projects and the safety of the raised funds [9][25][27] Financial Data - The financial reports for the third quarter are unaudited, and the company has confirmed the accuracy and completeness of the financial information [3][2] - As of September 30, 2025, the company has a repurchase account holding 5,199,548 shares, accounting for 1.25% of the total share capital [5] Fund Management - The company will use the idle funds to purchase high-security, liquid investment products from qualified financial institutions, including but not limited to large deposits, structured deposits, and cash management products [9][15] - The investment period for the cash management is valid for 12 months from the board's approval date, and the funds can be rolled over within this limit [16][20] Approval Process - The board of directors has authorized the management to make investment decisions within the approved limits and duration, including selecting financial institutions and signing relevant contracts [10][25] - The company’s sponsor, CITIC Securities, has provided a clear verification opinion on this matter [11][27] Investment Purpose - The purpose of using idle funds for cash management is to enhance the efficiency of fund utilization and increase company returns while ensuring the normal operation of investment projects [14][20] Risk Control Measures - The company will implement strict risk control measures, including regular monitoring of investment products and maintaining confidentiality regarding financial transactions [22][24]

辽宁成大生物股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开 第五届董事会第二十三次会议，审议通过了《关于使用部分闲置募集资金进行现 金管理的议案》，同意公司在保证不影响募投项目建设实施、募集资金使用计划和 保证募集资金安全的情况下，使用不超过人民币 7 亿元（含）的闲置募集资金进 行现金管理，用于购买安全性高、流动性好、具有合法经营资格的金融机构销售 的投资产品（包括但不限于大额存单、结构性存款、定期存款、协定存款等存款 类产品以及现金管理类理财产品），使用期限自董事会审议通过之日起 12 个月 （含）内有效。在上述额度和期限内，资金可以循环滚动使用。 公司董事会授权公司管理层在上述额度范围和期限内行使投资决策权并签署 相关文件，包括但不限于：选择合格的专业金融机构、明确现金管理金额、期间、 选择现金管理产品品种、签署合同及协议等，具体事项由公司财务部负责组织实 施。公司保荐机构中信证券股份有限公司对本事项出具了明确的核查意见。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意辽宁成大生物股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕3019 号）， ...

关于辽宁成大生物股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"保荐机构"或"中信证券"）作为辽宁 成大生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票 并在科创板上市的持续督导保荐机构，根据《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》等有关规定， 对公司使用部分闲置募集资金进行现金管理的事项进行了核查，具体情况如下： 中信证券股份有限公司 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意辽宁成大生物股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕3019 号），公司首次公开发 行人民币普通股（A）股 4,165 万股，每股发行价格为 110.00 元，募集资金总额 为人民币 458,150.00 万元；扣除各项发行费用后实际募集资金净额为人民币 434,137.94 万元。其中募投项目拟投入资金 204,000.00 万元，超募资金 230,137.94 万元。上述募集资金已经容诚会计师事务所(特殊普通合伙)于 2021 年 10 月 25 日 出具的《验资报告》（ ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥389,109,365.95, a decrease of 7.79% compared to the same period last year[3] - The total profit for the period was ¥65,186,981.20, down 50.99% year-on-year[3] - The net profit attributable to shareholders was ¥42,517,342.30, reflecting a decline of 61.17% compared to the previous year[3] - The basic earnings per share for the period was ¥0.10, a decrease of 62.96% year-on-year[4] - Total operating revenue for the first three quarters of 2025 was ¥1,095,886,627.32, a decrease of 15.9% compared to ¥1,302,689,599.82 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was ¥164,812,017.55, down 50.0% from ¥329,698,128.04 in the same period of 2024[19] - Basic and diluted earnings per share decreased to ¥0.40 from ¥0.80, reflecting a 50.0% decline[20] - The net profit for the first three quarters of 2025 was CNY 272,711,795.18, down 42.3% from CNY 472,995,635.30 in the first three quarters of 2024[28] Research and Development - Research and development expenses totaled ¥116,458,959.65, accounting for 29.93% of operating revenue, an increase of 3.08 percentage points[4] - The company experienced intensified competition in the domestic vaccine market, impacting revenue and increasing R&D expenses[8] - Research and development expenses increased slightly to ¥210,301,914.79 from ¥207,277,477.75, reflecting a growth of 1.0%[18] - Research and development expenses for the first three quarters of 2025 were CNY 163,365,806.38, an increase of 31.9% compared to CNY 123,849,598.01 in the same period of 2024[27] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥171,017,980.98, down 41.27% compared to the previous year[3] - Cash flow from operating activities generated a net amount of ¥171,017,980.98, down 41.3% from ¥291,178,061.86 in the previous year[23] - The company's cash flow from operating activities for the first three quarters of 2025 showed a net decrease of CNY 486,398,395.41 compared to a decrease of CNY 283,688,805.57 in the same period of 2024[24] - The total cash inflow from operating activities was ¥1,042,989,241.62 in 2025, a decrease of 16.8% from ¥1,254,326,005.47 in 2024[30] - The cash and cash equivalents at the end of September 2025 were CNY 4,011,653,051.38, down from CNY 4,260,916,535.96 at the end of 2024[24] - The company's cash and cash equivalents decreased to RMB 4,010,183,067.13 from RMB 4,496,464,173.92, representing a decline of 10.83%[13] Assets and Liabilities - The total assets at the end of the period were ¥9,802,754,278.51, a decrease of 2.48% from the end of the previous year[4] - The total liabilities decreased to RMB 415,573,793.76 from RMB 489,119,315.20, a reduction of 15.04%[16] - The total equity attributable to shareholders was ¥9,387,180,484.75, a decrease of 1.83% from the previous year-end[4] - The company's total current assets as of September 30, 2025, were CNY 7,065,602,021.25, a decrease from CNY 7,248,416,940.65 at the end of 2024[24] - The total assets as of September 30, 2025, amounted to CNY 10,212,076,773.29, a decrease from CNY 10,347,110,363.62 at the end of 2024[26] Investment Activities - Cash inflow from investment activities totaled ¥3,526,438,967.31, an increase from ¥3,205,987,693.27 in the same period of 2024[23] - Cash outflow from investment activities increased to ¥3,841,337,519.09 from ¥3,398,435,517.05, resulting in a net cash flow of -¥314,898,551.78[23] - The net cash flow from investment activities was -¥323,005,037.69 in 2025, compared to -¥281,258,222.92 in 2024, indicating a worsening position[30] - Total cash inflow from investment activities in 2025 was ¥3,353,272,988.02, an increase of 12.4% from ¥2,984,090,714.51 in 2024[30] Shareholder Information - The total equity attributable to shareholders decreased to RMB 9,387,180,484.75 from RMB 9,562,467,951.11, a decrease of 1.83%[16] - The company held 5,199,548 shares in its repurchase account, accounting for 1.25% of the total share capital as of September 30, 2025[11] Accounting Standards - The company will not apply new accounting standards starting from 2025[32]